Article
Impact of Pharmacogenomics on Clinical Outcomes for Patients Taking Medications With Gene-Drug Interactions in a Randomized Controlled Trial.
The Journal of clinical psychiatry - 31 Oct 2019
Thase Michael E, Parikh Sagar V, Rothschild Anthony J, Dunlop Boadie W, DeBattista Charles, Conway Charles R, Forester Brent P, Mondimore Francis M, Shelton Richard C, Macaluso Matthew, Li James, Brown Krystal, Jablonski Michael R, Greden John F
Abstract excerpt
OBJECTIVE: The objective of the Genomics Used to Improve DEpression Decisions (GUIDED) trial was to evaluate the utility of pharmacogenomic testing to improve outcomes among patients with major depressive disorder (MDD) who had not responded to at least 1 prior medication trial. The objective of the present analysis was to assess outcomes for the subset of patients expected to benefit from combinatorial...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
